Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
1.7K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants.

Acta neuropathologica·2026
Same author

Ultrasound modulates microglial activity and reduces neuroinflammation in a parameter-dependent manner.

NPJ acoustics·2026
Same author

Author Correction: UK Biobank at 20 - a growing, global resource for dementia research.

Nature reviews. Neurology·2026
Same author

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.

European journal of nuclear medicine and molecular imaging·2026
Same author

UK Biobank at 20 - a growing, global resource for dementia research.

Nature reviews. Neurology·2026

Related Experiment Video

Updated: Mar 14, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Personalised medicine for multiple sclerosis care.

Arie Gafson1, Matt J Craner2, Paul M Matthews3

  • 1Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 28, 2016
PubMed
Summary
This summary is machine-generated.

Personalised medicine aims to tailor multiple sclerosis (MS) treatments to individual patients by integrating clinical and biological data. This approach addresses challenges in managing MS heterogeneity and predicting treatment responses for better patient care.

Keywords:
Treatment responsemultiple sclerosisoutcome measurement

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Mar 14, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Area of Science:

  • Neurology
  • Personalised Medicine
  • Biomarkers

Background:

  • Multiple sclerosis (MS) management is complicated by diverse clinical presentations and variable treatment responses.
  • Current treatment selection requires balancing efficacy and adverse events for each patient.
  • The heterogeneity of MS poses significant challenges to optimizing patient care.

Purpose of the Study:

  • To review the challenges in personalising the management of multiple sclerosis (MS).
  • To propose an agenda for research and stakeholder engagement to advance personalised MS care.
  • To highlight the need for precise diagnosis and prognosis for effective treatment selection.

Main Methods:

  • Selective review of current literature on MS management and personalised medicine.
  • Discussion of predictive modeling integrating clinical and biological data.
  • Analysis of challenges in tailoring treatment and monitoring for individual MS patients.

Main Results:

  • Personalised medicine in MS requires precise diagnosis to predict prognosis and treatment response.
  • Integrating clinical, biological, and patient-reported data is crucial for predictive models.
  • Significant challenges exist in developing and implementing personalised approaches for MS.

Conclusions:

  • Personalised medicine offers a framework for improving MS patient care by tailoring treatments.
  • Further research and stakeholder collaboration are essential to overcome challenges in MS personalisation.
  • A focus on the individual patient is key to balancing treatment benefits and risks in MS management.